Ironwood Pharmaceuticals, Inc. (IRWD) P/E ratio

P/E ratio today
5.4×

Ironwood Pharmaceuticals, Inc. (IRWD) trades at 5.4× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 22.5×. That is 94.9% lower than the 443.0× of fiscal 2024. Figures as of 18 Nov 2026, 10:46 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/E ratio today
5.4×
P/E ratio, fiscal 2025
22.5×
Change on fiscal 2024
−94.9%
Highest on record
443.0×fiscal 2024
Lowest on record
3.6×fiscal 2021
Fiscal years on record
62019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Ironwood Pharmaceuticals, Inc. P/E ratio, in more detail

Today's figure is 75.9% below the fiscal 2025 year-end.

Across the 6 fiscal year-ends on record (2019–2025), the highest was 443.0× in fiscal 2024 and the lowest 3.6× in fiscal 2021. Today's P/E ratio is higher than at 17% of the 6 fiscal year-ends on record; their median is 19.9×.

History · 6 fiscal years

P/E ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Ironwood Pharmaceuticals, Inc. P/E ratio, year by year

Ironwood Pharmaceuticals, Inc. (IRWD) P/E ratio by fiscal year
Fiscal yearP/E ratioChangeYear endedShare price at year-endDiluted EPS
Today5.4×—$4.87—
202522.5× 94.9% down$3.37$0.15
2024443.0×—$4.43$0.01
2023——$11.44-$6.45
202212.9× 255.3% up$12.39$0.96
20213.6× 79.0% down$11.66$3.21
202017.3× 81.8% down$11.39$0.66
201995.1×—$13.31$0.14
2018——$8.68-$1.85
2017——$12.55—
2016——$12.81—
2015——$9.71—
2014——$12.83—
2013——$9.72-$1.97
2012——$9.28-$0.57
2011——$10.03-$0.54
2010——$8.67—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.

How to read it

It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.

More on IRWD

Ironwood Pharmaceuticals, Inc., figure by figure

Ironwood Pharmaceuticals, Inc. (IRWD) overview: price, valuation and scorecard

Ironwood Pharmaceuticals, Inc. P/E ratio: questions and answers

What is Ironwood Pharmaceuticals, Inc.'s P/E ratio?

Ironwood Pharmaceuticals, Inc. (IRWD) trades at 5.4× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 22.5×. That is 94.9% lower than the 443.0× of fiscal 2024.

Is Ironwood Pharmaceuticals, Inc.'s P/E ratio high or low compared with its own history?

Today's P/E ratio is higher than at 17% of the 6 fiscal year-ends on record; their median is 19.9×.

What are the highest and lowest P/E ratio figures on record for Ironwood Pharmaceuticals, Inc.?

Across the 6 fiscal year-ends on record (2019–2025), the highest was 443.0× in fiscal 2024 and the lowest 3.6× in fiscal 2021.

How is Ironwood Pharmaceuticals, Inc.'s P/E ratio calculated?

The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Ironwood Pharmaceuticals, Inc. it is on record here for 6 fiscal years, 2019 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ironwood Pharmaceuticals, Inc. (IRWD) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/IRWD/pe-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.